Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India

Abstract Macrolides are among the most widely prescribed antibiotics worldwide. However, their impact on the gut’s bacterial microbiota remains uncertain. We characterised the intestinal microbiota in 6–11 month-old infants in India who received a 3-day course of azithromycin or placebo during a ran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Edward P. K. Parker, Ira Praharaj, Jacob John, Saravanakumar Puthupalayam Kaliappan, Beate Kampmann, Gagandeep Kang, Nicholas C. Grassly
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f3da44427284428a948095cdcc56f312
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3da44427284428a948095cdcc56f312
record_format	dspace
spelling	oai:doaj.org-article:f3da44427284428a948095cdcc56f3122021-12-02T15:05:59ZChanges in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India10.1038/s41598-017-06862-02045-2322https://doaj.org/article/f3da44427284428a948095cdcc56f3122017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06862-0https://doaj.org/toc/2045-2322Abstract Macrolides are among the most widely prescribed antibiotics worldwide. However, their impact on the gut’s bacterial microbiota remains uncertain. We characterised the intestinal microbiota in 6–11 month-old infants in India who received a 3-day course of azithromycin or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588). In 60 infants per study arm, we sequenced the V4 region of the bacterial 16S rRNA gene in stool samples collected before and 12 days after finishing treatment. We also tested for the presence of common bacterial, viral, and eukaryotic enteropathogens in the same samples using real-time PCR in a Taqman array card (TAC) format. Azithromycin induced a modest decline in microbiota richness and a shift in taxonomic composition driven by a reduction in the relative abundance of Proteobacteria and Verrucomicrobia (specifically Akkermansia muciniphila). The former phylum includes pathogenic strains of Escherichia coli and Campylobacter spp. that declined in prevalence based on the TAC assay. These findings differ from previous observations among older children and adults in Europe and North America, suggesting that the effects of azithromycin on the bacterial microbiota may be specific to the age and geographic setting of its recipients.Edward P. K. ParkerIra PraharajJacob JohnSaravanakumar Puthupalayam KaliappanBeate KampmannGagandeep KangNicholas C. GrasslyNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Edward P. K. Parker Ira Praharaj Jacob John Saravanakumar Puthupalayam Kaliappan Beate Kampmann Gagandeep Kang Nicholas C. Grassly Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
description	Abstract Macrolides are among the most widely prescribed antibiotics worldwide. However, their impact on the gut’s bacterial microbiota remains uncertain. We characterised the intestinal microbiota in 6–11 month-old infants in India who received a 3-day course of azithromycin or placebo during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588). In 60 infants per study arm, we sequenced the V4 region of the bacterial 16S rRNA gene in stool samples collected before and 12 days after finishing treatment. We also tested for the presence of common bacterial, viral, and eukaryotic enteropathogens in the same samples using real-time PCR in a Taqman array card (TAC) format. Azithromycin induced a modest decline in microbiota richness and a shift in taxonomic composition driven by a reduction in the relative abundance of Proteobacteria and Verrucomicrobia (specifically Akkermansia muciniphila). The former phylum includes pathogenic strains of Escherichia coli and Campylobacter spp. that declined in prevalence based on the TAC assay. These findings differ from previous observations among older children and adults in Europe and North America, suggesting that the effects of azithromycin on the bacterial microbiota may be specific to the age and geographic setting of its recipients.
format	article
author	Edward P. K. Parker Ira Praharaj Jacob John Saravanakumar Puthupalayam Kaliappan Beate Kampmann Gagandeep Kang Nicholas C. Grassly
author_facet	Edward P. K. Parker Ira Praharaj Jacob John Saravanakumar Puthupalayam Kaliappan Beate Kampmann Gagandeep Kang Nicholas C. Grassly
author_sort	Edward P. K. Parker
title	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
title_short	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
title_full	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
title_fullStr	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
title_full_unstemmed	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India
title_sort	changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south india
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/f3da44427284428a948095cdcc56f312
work_keys_str_mv	AT edwardpkparker changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT irapraharaj changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT jacobjohn changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT saravanakumarputhupalayamkaliappan changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT beatekampmann changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT gagandeepkang changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia AT nicholascgrassly changesintheintestinalmicrobiotafollowingtheadministrationofazithromycininarandomisedplacebocontrolledtrialamonginfantsinsouthindia
_version_	1718388680637284352

Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India

Ejemplares similares